iPSC technology-Powerful hand for disease modeling and therapeutic screen

Changsung Kim

Research output: Contribution to journalShort survey

16 Scopus citations

Abstract

Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed.

Original languageEnglish (US)
Pages (from-to)256-265
Number of pages10
JournalBMB Reports
Volume48
Issue number5
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Disease modeling
  • Drug screen
  • IPSC
  • Patient specific therapy
  • Stem cell

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this